Scolr Pharma, Inc. has entered into a research collaboration with a US based biopharmaceutical company to develop an oral formulation of a promising antiviral compound using Scolr's proprietary CDT drug delivery platform.

The compound under development has the potential to be used as a treatment against influenza. The goal of the programme is to enhance the bioavailability of partner's compound, to facilitate oral administration. If successful, the parties expect to enter a license agreement, which would provide for the potential commercialisation of a significant new pharmaceutical product.

Alan M. Mitchel, Scolr Pharma's senior vice president, said, "We believe this collaborative agreement is another important affirmation of the breadth of our proprietary CDT drug delivery technology. We look forward to working closely with our partner on this potentially important new pharmaceutical application. This is our fourth partnering relationship announced over the last several quarters."

Scolr Pharma, Inc. is a specialty pharmaceutical company leveraging formulation expertise and its patented CDT platform to introduce distinctive and novel OTC products, prescription drugs and dietary supplements. Scolr Pharma's CDT drug delivery platform provides distinctive products with tangible benefits for the consumer and competitive commercial advantages for licensees.